...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024

OK, then don't settle down.  No skin of my back!

 

Koo

Share
New Message
Please login to post a reply